2.29
4.09%
0.09
After Hours:
2.29
Beyondspring Inc stock is traded at $2.29, with a volume of 59,465.
It is up +4.09% in the last 24 hours and up +12.25% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
See More
Previous Close:
$2.20
Open:
$2.21
24h Volume:
59,465
Relative Volume:
2.39
Market Cap:
$92.29M
Revenue:
$1.55M
Net Income/Loss:
$-27.51M
P/E Ratio:
-2.6941
EPS:
-0.85
Net Cash Flow:
$-50.09M
1W Performance:
+10.10%
1M Performance:
+12.25%
6M Performance:
-35.85%
1Y Performance:
+186.25%
Beyondspring Inc Stock (BYSI) Company Profile
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Sep-09-21 | Initiated | Robert W. Baird | Outperform |
Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-11-21 | Initiated | BofA Securities | Buy |
Dec-29-20 | Initiated | Evercore ISI | Outperform |
Feb-07-20 | Initiated | Jefferies | Buy |
Jan-10-20 | Initiated | Nomura | Buy |
Dec-03-19 | Initiated | William Blair | Outperform |
Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
BYSI: BeyondSpring Inc. Stock Surges 7.27% Amid Market Fluctuati - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Acadian Asset Management LLC Has $34,000 Stock Position in BeyondSpring Inc. (NASDAQ:BYSI) - Defense World
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC - MSN
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com India
BeyondSpring reports safer NSCLC therapy option - Investing.com India
BeyondSpring reports safer NSCLC therapy option - Investing.com
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - StockTitan
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - StockTitan
BeyondSpring presented interim Phase 2 data on 303 Study - TipRanks
BeyondSpring Presents Efficacy/Safety Results from a Phase - GlobeNewswire
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase - GlobeNewswire
BeyondSpring (NASDAQ:BYSI) Trading Up 3.3% - MarketBeat
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type... - Markets Insider
BeyondSpring announces Dublin-3 final phase 3 efficacy data - TipRanks
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - GlobeNewswire
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - Yahoo Finance
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - StockTitan
BeyondSpring Announces Oral Presentation at the 2024 World - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - StockTitan
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - Yahoo Finance
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? - Yahoo Finance
BeyondSpring Inc. Reports Mid-Year Financials - TipRanks
Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve
Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - PR Newswire UK
BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.5% - MarketBeat
BYSI (BeyondSpring) EV-to-Revenue : 40.75 (As of Aug. 19, 2024) - GuruFocus.com
BYSI (BeyondSpring) GF Value Rank : 10 (As of Aug. 18, 2024) - GuruFocus.com
BYSI (BeyondSpring) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023) - GuruFocus.com
BioWorld Cancer Index drops overall; Blueprint, TG catapulted in Q1 - BioWorld Online
Chemotherapy Induced Neutropenia Market Forecasted to Surge - openPR
SEED Therapeutics (SEED) Enters into Strategic Research - GlobeNewswire
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - StockTitan
Global Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsight - 新浪香港
Global Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsight - India Shorts
Drugs for Traveler’s Diarrhea Industry to Witness an Outstanding Growth by 2030 |GSK, Salix Pharmaceuticals, Chiesi Farm – Moose Gazette - Moose Gazette
O Shaughnessy Asset Management LLC Buys 21,202 Shares of Haleon plc (NYSE:HLN) - Defense World
Cencora (NYSE:COR) Releases FY 2024 Earnings Guidance - Defense World
Public Employees Retirement Association of Colorado Sells 1,333 Shares of WestRock (NYSE:WRK) - Defense World
Leatt (OTCMKTS:LEAT) Stock Passes Above 50 Day Moving Average of $6.76 - Defense World
Schwarz Dygos Wheeler Investment Advisors LLC Sells 5,532 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Apple Inc. (NASDAQ:AAPL) Shares Acquired by Westchester Capital Management Inc. - Defense World
Rehmann Capital Advisory Group Sells 743 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
SG Americas Securities LLC Invests $69,000 in Lithium Americas Corp. (NYSE:LAC) - Defense World
Vital Energy (VTLE) Set to Announce Quarterly Earnings on Wednesday - Defense World
UBS ETRACS 2xLeveraged Long Wells Fargo Business Development Company Index ETN (NYSEARCA:BDCL) Stock Price Crosses Below Two Hundred Day Moving Average of $2.44 - Defense World
OneSoft Solutions (OTCMKTS:OSSIF) Stock Price Passes Below 200 Day Moving Average of $0.57 - Defense World
Caspase 3 Market – 37% of Growth to Originate from APAC -Aptose Biosciences Inc, BeyondSpring Pharmaceuticals Inc, Conat – Moose Gazette - Moose Gazette
Acadian Asset Management LLC Trims Position in Natural Health Trends Corp. (NASDAQ:NHTC) - Defense World
Acadian Asset Management LLC Decreases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):